Integra LifeSciences (NASDAQ:IART) and Alpha Tau Medical (NASDAQ:DRTS) Head to Head Contrast

Alpha Tau Medical (NASDAQ:DRTS) and Integra LifeSciences (NASDAQ:IART) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings for Alpha Tau Medical and Integra LifeSciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	0	0	2	0	3.00
Integra LifeSciences	3	4	1	0	1.75

Alpha Tau Medical currently has a consensus target price of $8.00, indicating a potential upside of 158.06%. Integra LifeSciences has a consensus target price of $23.00, indicating a potential upside of 5.50%. Given Alpha Tau Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Alpha Tau Medical is more favorable than Integra LifeSciences.

Profitability

This table compares Alpha Tau Medical and Integra LifeSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-38.62%	-29.89%
Integra LifeSciences	-0.42%	12.35%	4.82%

Valuation & Earnings

This table compares Alpha Tau Medical and Integra LifeSciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$29.16 million	($0.43)	-7.21
Integra LifeSciences	$1.56 billion	1.07	$67.74 million	($0.09)	-242.22

Integra LifeSciences has higher revenue and earnings than Alpha Tau Medical. Integra LifeSciences is trading at a lower price-to-earnings ratio than Alpha Tau Medical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by company insiders. Comparatively, 3.1% of Integra LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Alpha Tau Medical has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Summary

Integra LifeSciences beats Alpha Tau Medical on 7 of the 13 factors compared between the two stocks.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.